Skip to content

Hepatitis B reactivation after switch to injectable treatment: rare, but proceed with caution

Dr Luz Martin at HIV Glasgow 2026. She is standing at a lectern, talking into a microphone.

Injectable HIV treatment does as well as daily pills in real-world settings

Dr Alisa Timiryasova at HIV Glasgow 2026. She is standing behind a lectern, with a screen behind her.

Dolutegravir resistance has not risen in Lesotho cohort

Professor Niklaus Labhardt at HIV Glasgow 2026. He is standing at a lectern.

European guidelines widen access to two-drug HIV treatment

Dr Annalisa Marinosci at HIV Glasgow 2026. She is standing behind a lectern.

A pair of antibodies keeps HIV undetectable by ‘bolting the door and masking the key’

Dr Martin Markowitz at HIV Glasgow 2026. He is standing behind a lectern.

“Normal is the perfect word”: participants describe switching to weekly HIV treatment

Professor Chloe Orkin at HIV Glasgow 2026.

From “good news” to “failure”: how French participants experienced an HIV remission trial

A man talks to a healthcare professional.

'We finally understand what we have to do': antibody studies point the way to an HIV cure

A scientist works in a lab.

Lean people with HIV can still develop fatty liver disease

Florence Bascombe at AIDS 2026. She is standing at a lectern, talking into a microphone.